Helene Roelofs
Overview
Explore the profile of Helene Roelofs including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
48
Citations
3751
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Reinders M, Groeneweg K, Hendriks S, Bank J, Dreyer G, de Vries A, et al.
Am J Transplant
. 2021 Feb;
21(9):3055-3065.
PMID: 33565206
After renal transplantation, there is a need for immunosuppressive regimens which effectively prevent allograft rejection, while preserving renal function and minimizing side effects. From this perspective, mesenchymal stromal cell (MSC)...
2.
Dreyer G, Groeneweg K, Heidt S, Roelen D, van Pel M, Roelofs H, et al.
Am J Transplant
. 2020 Apr;
20(10):2905-2915.
PMID: 32277568
Mesenchymal stromal cells (MSC) hold promise as a novel immune-modulatory therapy in organ transplantation. First clinical studies have used autologous MSCs; however, the use of allogeneic "off-the-shelf" MSCs is more...
3.
Das R, Roosloot R, van Pel M, Schepers K, Driessen M, Fibbe W, et al.
J Transl Med
. 2019 Jul;
17(1):241.
PMID: 31340829
Background: Cell-based therapies have the potential to become treatment options for many diseases, but efficient scale-out of these therapies has proven to be a major hurdle. Bioreactors can be used...
4.
Barnhoorn M, Wasser M, Roelofs H, Maljaars P, Molendijk I, Bonsing B, et al.
J Crohns Colitis
. 2019 Jun;
14(1):64-70.
PMID: 31197361
Background And Aims: The long-term safety and efficacy of allogeneic bone marrow-derived mesenchymal stromal cell [bmMSC] therapy in perianal Crohn's disease [CD] fistulas is unknown. We aimed to provide a...
5.
Trento C, Bernardo M, Nagler A, Kuci S, Bornhauser M, Kohl U, et al.
Biol Blood Marrow Transplant
. 2018 Jul;
24(11):2365-2370.
PMID: 30031938
The immunosuppressive properties of mesenchymal stromal cells (MSC) have been successfully tested to control clinical severe graft-versus host disease and improve survival. However, clinical studies have not yet provided conclusive...
6.
Broekman W, Khedoe P, Schepers K, Roelofs H, Stolk J, Hiemstra P
Thorax
. 2018 Apr;
73(6):565-574.
PMID: 29653970
COPD is characterised by tissue destruction and inflammation. Given the lack of curative treatments and the progressive nature of the disease, new treatments for COPD are highly relevant. In vitro...
7.
Broekman W, Roelofs H, Zarcone M, Taube C, Stolk J, Hiemstra P
ERJ Open Res
. 2016 Oct;
2(2).
PMID: 27730190
Autologous bone marrow-derived mesenchymal stromal cells (BM-MSCs) are evaluated for clinical use in chronic obstructive pulmonary disease (COPD) patients, but it is unclear whether COPD affects BM-MSCs. To investigate this,...
8.
den Haan M, van Zuylen V, Pluijmert N, Schutte C, Fibbe W, Schalij M, et al.
PLoS One
. 2016 Apr;
11(4):e0152938.
PMID: 27050443
Background: Human mesenchymal stromal cells (MSCs) have been reported to preserve cardiac function in myocardial infarction (MI) models. Previously, we found a beneficial effect of intramyocardial injection of unstimulated human...
9.
Broekman W, Amatngalim G, de Mooij-Eijk Y, Oostendorp J, Roelofs H, Taube C, et al.
Respir Res
. 2016 Jan;
17:3.
PMID: 26753875
Background: Mesenchymal stromal cells (MSCs) are investigated for their potential to reduce inflammation and to repair damaged tissue. Inflammation and tissue damage are hallmarks of chronic obstructive pulmonary disease (COPD)...
10.
Reinders M, Dreyer G, Bank J, Roelofs H, Heidt S, Roelen D, et al.
J Transl Med
. 2015 Nov;
13:344.
PMID: 26537851
Background: Mesenchymal stromal cells (MSC) may serve as an attractive therapy in renal transplantation due to their immunosuppressive and reparative properties. While most studies have used autologous MSCs, allogeneic MSCs...